Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Nephrology

Building Your Care Team and Seeking Specialized Testing

At a Glance

For FSGS, the right specialist team can clarify whether the biopsy pattern is primary, genetic, or secondary. Genetic testing may guide treatment, transplant planning, and donor safety, while expert biopsy review and clinical trials can support difficult cases.

Managing Focal Segmental Glomerulosclerosis (FSGS) effectively requires a team that understands FSGS as a complex “pattern of injury” rather than a single disease [1]. Because your treatment path depends entirely on correctly identifying the cause, the expertise of your medical team is an important asset [2].

Finding the Right Expertise

Many patients with FSGS are successfully managed by general nephrologists. However, a glomerular-disease or transplant referral is particularly useful when the diagnosis is uncertain, the disease is steroid-resistant, genetic testing is complex, or a transplant is being considered [3][2].

  • The Renal Pathologist: Your biopsy is the “roadmap” for your care. Ideally, your biopsy should be reviewed by a pathologist who specializes in kidneys. Biopsy review should integrate light microscopy, immunofluorescence, and electron microscopy [2]. The sclerotic lesion is primarily identified on light microscopy, while electron microscopy supports the assessment and helps exclude other diseases [4].
  • The Academic Advantage: Many patients find that “Glomerular Centers” at major academic universities offer access to multidisciplinary teams, including specialized pharmacists, dietitians, and clinical trial coordinators, which can be useful when available [2][5].

The Role of Genetic Testing

Genetic testing has become a vital tool in modern FSGS care. Identifying a genetic cause can be life-changing, as it often means you can avoid the high-dose steroids and immunosuppressants that are standard for Primary FSGS but generally do not work for genetic forms [6][7].

When to Consider Testing

Your doctor may recommend genetic testing—often using a kidney-disease gene panel or whole-exome sequencing—based on several factors [8][9]:

  • Age at Onset: Testing is highly recommended for children and young adults based on age at onset [10][11].
  • Steroid Resistance: If your protein levels do not drop after a standard course of steroids, a genetic mutation may be the reason [12].
  • Family History: If a close relative has had kidney disease or required dialysis, testing can identify a familial link [8].
  • Atypical Features: If you have “extrarenal” symptoms (health issues outside the kidneys, like hearing or eye problems), this may suggest a syndromic form of FSGS [13].
  • Ancestry: People of recent West African ancestry may be tested for APOL1 risk variants [14][15]. APOL1 risk variants are complex susceptibility factors rather than proof of a monogenic FSGS diagnosis, and they do not by themselves determine treatment.

Genetic testing should include pre- and post-test genetic counseling to explain the possibility of a negative result, a variant of uncertain significance, privacy considerations, and insurance implications.

Planning for the Future

Genetic testing is also a cornerstone of transplant planning.

  • Recurrence Risk: A confirmed kidney-intrinsic genetic diagnosis generally means the risk of FSGS returning in a new kidney is usually very low, whereas the risk is much higher for Primary FSGS (ranges of 30-40% or more depending on the cohort) [16][17].
  • Donor Safety: If a family member wants to donate a kidney, donor assessment requires variant interpretation, clinical evaluation, and genetic counseling to evaluate risks and ensure the donor does not carry the same mutation or high-risk APOL1 variants [18][19].

Engaging with Clinical Research

Because FSGS treatment is rapidly evolving, a high-quality care team should also discuss the possibility of clinical trials [5]. Trials are currently investigating new targeted therapies for different categories of FSGS, including those specifically for primary disease or specific genetic mutations like TRPC6 [NCT07220083]. Participating in a trial may offer access to emerging treatments while helping advance the global understanding of this complex condition, though they require careful consideration of experimental risks and protocols [NCT06500702][NCT04065438].

Common questions in this guide

When should I ask for a glomerular disease specialist or a second opinion for FSGS?
Many people with FSGS can be treated by a general nephrologist. A referral to a glomerular-disease center or transplant specialist may help when the diagnosis is uncertain, the disease is steroid-resistant, genetic testing is complex, or a transplant is being considered. A second opinion can also provide access to a kidney-focused pathologist and a broader care team.
Why does a renal pathologist need to review my FSGS biopsy?
A renal pathologist reviews the biopsy using light microscopy, immunofluorescence, and electron microscopy. This helps identify the scarring pattern and look for findings that point to another kidney disease. Expert review is especially useful when the diagnosis or treatment plan is uncertain.
Who should consider genetic testing for FSGS?
Testing is often considered when FSGS begins in childhood or young adulthood, does not respond to steroids, runs in the family, or is accompanied by hearing, eye, or other health problems outside the kidneys. People with recent West African ancestry may also be evaluated for APOL1 risk variants. Your clinician can help decide which test and counseling are appropriate.
How could a genetic FSGS result change my treatment?
Finding a kidney-related genetic cause may show that high-dose steroids or other immune-suppressing medicines are unlikely to help. This can help some patients avoid unnecessary treatment and may influence monitoring and transplant planning. Genetic counseling before and after testing can explain negative results, uncertain findings, privacy, and insurance issues.
Does genetic FSGS come back after a kidney transplant?
A confirmed genetic change within the kidney usually means FSGS is unlikely to return in a transplanted kidney. Recurrence is more common with primary FSGS and has been reported at about 30–40% or higher in some groups. The actual risk depends on the cause and the individual clinical history.
What should be checked before a relative donates a kidney?
Before a relative donates a kidney, both the donor and recipient may need genetic testing, careful review of any genetic finding, a medical evaluation, and genetic counseling. These steps help assess whether the donor could carry the same change or high-risk APOL1 variants and protect the donor’s long-term health.
Are clinical trials available for different types of FSGS?
FSGS clinical trials are studying targeted treatments for different forms of the condition, including primary FSGS and some genetic subtypes such as TRPC6-related disease. A nephrologist or research coordinator can explain eligibility, possible benefits, experimental risks, and study requirements before you decide.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Focal segmental glomerulosclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does our local center have experience managing glomerular diseases, or should I seek a second opinion from a dedicated Glomerular Center for this complex case?
  2. 2.Given my diagnosis and age at onset, should I undergo genetic testing?
  3. 3.Can you explain how a confirmed genetic cause might change my current treatment plan or help me avoid unnecessary immunosuppression?
  4. 4.If I am considering a living-related donor for a future transplant, how would genetic testing for both me and the donor help evaluate the risks?
  5. 5.Are there any active clinical trials for my specific type of FSGS (Primary, Genetic, or Secondary) that I should consider joining?
  6. 6.Has a renal pathologist with expertise in glomerular injury reviewed my biopsy including light, immunofluorescence, and electron microscopy?

References

References (19)
  1. 1

    Focal Segmental Glomerulosclerosis.

    Rosenberg AZ, Kopp JB

    Clinical journal of the American Society of Nephrology : CJASN 2017; (12(3)):502-517 doi:10.2215/CJN.05960616.

    PMID: 28242845
  2. 2

    FSGS: from pathogenesis to the histological lesion.

    Angioi A, Pani A

    Journal of nephrology 2016; (29(4)):517-23 doi:10.1007/s40620-016-0333-2.

    PMID: 27392958
  3. 3

    Indications for genetic testing in adults with focal segmental glomerulosclerosis.

    Pilco-Terán M, Shabaka A, Furlano M, et al.

    Nefrologia 2025; (45(2)):135-149 doi:10.1016/j.nefroe.2025.02.001.

    PMID: 39952830
  4. 4

    Electron microscopic findings suggestive of focal and segmental glomerulosclerosis in patients with steroid-resistant nephrotic syndrome.

    Nili F, Saboori F, Jahanzad I, Mehrazma M

    Ultrastructural pathology 2019; (43(1)):6-12 doi:10.1080/01913123.2019.1584258.

    PMID: 30835594
  5. 5

    Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group.

    Mirioglu S, Daniel-Fischer L, Berke I, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2024; (39(4)):569-580 doi:10.1093/ndt/gfae025.

    PMID: 38341276
  6. 6

    When Genes Reveal the Truth: Alport Syndrome Mimicking Steroid-Resistant Nephrotic Syndrome.

    Dotis J, Kondou A, Liapis G, et al.

    Pediatric reports 2025; (18(1)) doi:10.3390/pediatric18010003.

    PMID: 41562995
  7. 7

    Tissue is the issue: when a second biopsy reveals the true diagnosis.

    Bogaert AM, Hoorens A, Praet M, et al.

    Clinical kidney journal 2021; (14(1)):429-431 doi:10.1093/ckj/sfz165.

    PMID: 33564449
  8. 8

    Identification of disease-causing variants by comprehensive genetic testing with exome sequencing in adults with suspicion of hereditary FSGS.

    Braunisch MC, Riedhammer KM, Herr PM, et al.

    European journal of human genetics : EJHG 2021; (29(2)):262-270 doi:10.1038/s41431-020-00719-3.

    PMID: 32887937
  9. 9

    Genetic testing in focal segmental glomerulosclerosis: in whom and when?

    Tato AM, Carrera N, García-Murias M, et al.

    Clinical kidney journal 2023; (16(11)):2011-2022 doi:10.1093/ckj/sfad193.

    PMID: 37915894
  10. 10

    Genetic testing in steroid-resistant nephrotic syndrome: when and how?

    Lovric S, Ashraf S, Tan W, Hildebrandt F

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2016; (31(11)):1802-1813 doi:10.1093/ndt/gfv355.

    PMID: 26507970
  11. 11

    The Clinical and Genetic Features in Chinese Children With Steroid-Resistant or Early-Onset Nephrotic Syndrome: A Multicenter Cohort Study.

    Zhu X, Zhang Y, Yu Z, et al.

    Frontiers in medicine 2022; (9()):885178 doi:10.3389/fmed.2022.885178.

    PMID: 35755072
  12. 12

    Whole-exome sequencing of a multicenter cohort identifies genetic changes associated with clinical phenotypes in pediatric nephrotic syndrome.

    Jiao J, Wang L, Ni F, et al.

    Genes & diseases 2022; (9(6)):1662-1673 doi:10.1016/j.gendis.2022.03.023.

    PMID: 36157477
  13. 13

    Monogenic Causes Identified in 23.68% of Children with Steroid-Resistant Nephrotic Syndrome: A Single-Centre Study.

    Zhang L, Zhao F, Ding G, et al.

    Kidney diseases (Basel, Switzerland) 2024; (10(1)):61-68 doi:10.1159/000534853.

    PMID: 38322629
  14. 14

    Update on APOL1 and chronic kidney diseases in children.

    Varner JD, Ilori TO, Gbadegesin RA

    Pediatric nephrology (Berlin, Germany) 2026; (41(11)):3813-3826 doi:10.1007/s00467-026-07384-6.

    PMID: 42249201
  15. 15

    APOL1 risk genotype in Europe: Data in patients with focal segmental glomerulosclerosis and after renal transplantation

    Servais A, Gribouval O, Gaillard F, Antignac C

    Nephrologie & therapeutique 2019; (15 Suppl 1()):S85-S89 doi:10.1016/j.nephro.2019.02.005.

    PMID: 30981401
  16. 16

    Monogenic variants drive low recurrence risk in pediatric steroid-resistant nephrotic syndrome after kidney transplantation: a high-consanguinity cohort.

    ALQattan F, Azzam A, Alkanani H, et al.

    Pediatric nephrology (Berlin, Germany) 2026; (41(11)):4127-4139 doi:10.1007/s00467-026-07430-3.

    PMID: 42350677
  17. 17

    Focal Segmental Glomerulosclerosis: State-of-the-Art and Clinical Perspective.

    Shabaka A, Tato Ribera A, Fernández-Juárez G

    Nephron 2020; (144(9)):413-427 doi:10.1159/000508099.

    PMID: 32721952
  18. 18

    Diagnosing FSGS without kidney biopsy - a novel INF2-mutation in a family with ESRD of unknown origin.

    Münch J, Grohmann M, Lindner TH, et al.

    BMC medical genetics 2016; (17(1)):73 doi:10.1186/s12881-016-0336-9.

    PMID: 27733133
  19. 19

    A pragmatic approach to selective genetic testing in kidney transplant candidates.

    Nissaisorakarn P, Fadakar PK, Safa K, et al.

    Frontiers in transplantation 2023; (2()):1342471 doi:10.3389/frtra.2023.1342471.

    PMID: 38993907

This page is for informational purposes only and does not constitute medical advice. It explains FSGS care teams, biopsy review, and genetic testing; consult your nephrologist and genetic counselor about your situation.